
Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 8-K

BIOANALYTICAL SYSTEMS INC

Form 8-K January 22, 2014		
UNITED STATES		
SECURITIES AND EXCHANGE COMMISSION		
Washington, D.C. 20549		
FORM 8-K		
CURRENT REPORT		
Pursuant to Section 13 or 15(d) of the Securities Exchar	nge Act of 1934	
Date of Report (Date of earliest event reported): January 22, 2014		
BIOANALYTICAL SYSTEMS, INC. (Exact name of registrant as specified in its charter)		
Indiana (State or other jurisdiction of incorporation or organization)	0-23357 (Commission File Number)	35-1345024 (I.R.S. Employer Identification No.)
2701 KENT AVENUE WEST LAFAYETTE, INDIANA 47906-1382		

Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 8-K



"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

Item 7.01 Regulation FD Disclosure

Bioanalytical Systems, Inc. ("BASi") previously announced that the Company will be presenting at the Tenth Annual Noble Financial Capital Markets Equity Conference on Wednesday, January 22, 2014 at 10:00 a.m. EST in Room 1 at the Club Med in Sandpiper Bay, Florida. The audio high-definition video of BASi's presentation will be webcast live on the Investors tab at www.BASinc.com or at www.Noblefcm.com. The webcast requires the installation of Microsoft Silverlight viewer and will be available for replay at BASi's website for 90 days after the presentation. Copies of the presentation materials are also available online from the Investors tab at www.BASinc.com and are attached as Exhibit 99.1 to this Current Report and are incorporated herein by reference. The Company may also use these slides at future conferences.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Slide Presentation for Tenth Annual Noble Financial Capital Markets Equity Conference to be held on January 22, 2014.

SIGNATURES

Edgar Filing: BIOANALYTICAL SYSTEMS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bioanalytical Systems, Inc.

Date: January 22, 2014 By: /s/Jacqueline M. Lemke Jacqueline M. Lemke

President and Chief Executive Officer and Chief Financial Officer and Vice President—Finance